|
Q3 FY2026
As of Aug 31, 2026
|
Q2 FY2026
As of May 31, 2026
|
Q1 FY2026
As of Feb 28, 2026
|
Q4 FY2025
As of Nov 30, 2025
|
Q3 FY2025
As of Aug 31, 2025
|
Q2 FY2025
As of May 31, 2025
|
Q1 FY2025
As of Feb 28, 2025
|
Q4 FY2024
As of Nov 30, 2024
|
Q3 FY2024
As of Aug 31, 2024
|
Q2 FY2024
As of May 31, 2024
|
Q1 FY2024
As of Feb 29, 2024
|
Q4 FY2023
As of Nov 30, 2023
|
Q3 FY2023
As of Aug 31, 2023
|
Q2 FY2023
As of May 31, 2023
|
Q1 FY2023
As of Feb 28, 2023
|
Q4 FY2022
As of Nov 30, 2022
|
Q3 FY2022
As of Aug 31, 2022
|
Q2 FY2022
As of May 31, 2022
|
Q1 FY2022
As of Feb 28, 2022
|
Q4 FY2021
As of Nov 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Marketable securities, current | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Marketable securities, non‑current | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and stockholdersʼ equity | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||||
| Operating lease liabilities, current | ||||||||||||||||||||
| Deferred revenue, current | ||||||||||||||||||||
| Deferred collaboration funding, current | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Operating lease liabilities, net of current portion | ||||||||||||||||||||
| Deferred revenue, net of current portion | ||||||||||||||||||||
| Deferred collaboration funding, net of current portion | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholdersʼ equity: | ||||||||||||||||||||
| Preferred stock, $0.001 par value— 10,000,000 shares authorized as of August 31, 2026 and November 30, 2025; no shares issued and outstanding as of August 31, 2026 and November 30, 2025 | ||||||||||||||||||||
| Common stock, $0.001 par value— 500,000,000 shares authorized as of August 31, 2026 and November 30, 2025; 109,200,394 and 101,807,484 shares issued and outstanding as of August 31, 2026 and November 30, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholdersʼ equity | ||||||||||||||||||||
| Total liabilities and stockholdersʼ equity | ||||||||||||||||||||
Loading...
